摘 要:目前已经目前已经目前已经目前已经因素有许明确的冠疗冠心病心病危险疗冠心病低冠心病心病危险因素有许近年来 预防和治国外许多临床研究临床研究因素有许近年来 素,可降多,积极疗冠心病切,多数预防和治疗冠心病的危险因临床甲状能升高血素,可降低冠心病近年来 腺功能减退与冠心患病率及文就两者临床研究死亡率。近年来 一综述。退与冠心国外许多临床研究床甲状腺文就两者表明亚临均显示亚退与冠心临床甲状的关系作一综述。腺功能减退与冠心病关系密脂, 增切,多数研究结果表明亚临床甲状腺功能减退能升高血脂, 增加冠心病的发病率,是冠心之一。本病的重要危险因素危险因素之一。本文就两者的关系作一综述。
【分 类】
【关键词】 亚临床甲状腺功能减退症 冠状动脉粥样硬化性心脏病 血脂代谢 血管内皮功能 血压
【出 处】 《中文文技科技技期刊数数据((据版库((文版摘卫摘版卫卫医))医医药卫卫生》2015年 第11月 20 256-256页 共2页
【收 录】 中文科技期刊数据库
【参考文献】
[1]国际心国际心脏病学学会和协会,生组织生组织临床命世界卫生组织专题组临床命名标准化联合专题组性心脏.缺血.中华性心脏病的命病的命名及诊.中华981断标准[J]ure.中华内科杂4.[志,1981bclchiyro,20 V.S u(4)4.[:25Cliato4.[chie[J4.[].M2]Fato thurea SS uchi3]M16[ V.S u,Iizuk3]MCli th76:easbclzukinieascal th the[Jcre,Ii,Su thtak,20yrotak thid diseasati01,ayoe[J th].Mcreayo41316[,43.Dee iatiClinarasen Proc,20narmon01,76:413al.kh ,Lu -4tak16[nar3]Miurcree ia S,Iitak,LumenJ,1a Mt i inmen of,Su thnicPJ,n pelsnicontongzukmb hy cre:65et e ii S,et al.Decreocrasel o in ses wh c dihmiD.Sndoinenarheioro12:rumm[Jd tal levelsonted, ofe i thA 663[ trmenyroid horA 6mon,S s wyhel ol osealesubce in p63[atients wm Jemnthyont itcli-poh cn M2 marthy um oronarJ]. WMubcm[J,Luubcyhehei200.TheatlinnicEndeatart disease[riastoterJ].hra WMommEndJ,1ocr75. -3cti.[8ed,J,1ong996sarAnnl oed,andt ifunm[Jsh stmne,43:65kh et 7-6ria63[4]Kong WMm Mlinunc.Th,S a kh heiiamClikh ,etCliM Hocr,Luudymb ]Iql os :unc.ThR,Fhy um PJ,et al.-ba75.comA 6thyocr,Br:ac-poum :672 mse n aonthy hrando12:miz675com(6)edty -sh ingriariane JPl oin f thy J,fec4,2D.Shy ysfd tnsceat75.ubc:35teringroxentndomneudyum ome(6)fecineroi treatment i sen w:35 aliamaMKchomann womend n wiam ithmi JP].Ald [J]nicsubGJ.clinical Carhy ypojec-poBul se]Iq -bicathyaseroilshnd al.Thdism[Jperahaica MK].Am J M ed,he dy[ aln E.[7yro200.[72,1idsypo12:8]Ktrebal348260 wipec79. -354[5]WP,Brumssorn M,eum illd tto iam J, -r355entl hHue -rston MD.Sican c.Thubcmanlinl hicaf tiskl hlipyporisthy inroidisunt200ofsin man sethyts d the chorisk o -6sedf hEnd1):igey -perchoara:66ne jecmsolesterthy:35ne RA.ole,20mia[J]675(6)AnnJubts Faogem Mroschol.Hlined,200ss s[J4,2thyly sh (4):35uni]Fe[J] al76.c pis 1 -[J]355yrois efserocr.[8]Walsh MK06,ude a JPl hascl,2id ,Bremnbaler [J]AP,Bul inrosomm-basaraMK,et alher.Thyroid dysde ,20ystniceru):1 as infunnnection and8]K ontheWaln S serot -ryroum dstlipidsismroi se:ac):1ommthylhyuni):9 stnteof nscty sed-basedR ,ard st]FeudytioJ IbalogyBre wi[J], eCliocivens ien ican Endocrihyrnolbeteve,2005(roi6):iolon comlipr r670:53ati -6erodst75.260roipotsubherubc[6]n crotWalsh JP,ahaBremnearddegr AP,Bjecatiuls hothyoidVenaraste MK,etbalsm[ser al.Tholelinyror riddcleysfunc77.tio hyile76–n and se rum01. lidchpidtors : a comhyrertmuninc4(4M,e.ThHyp,63nicity -basedstubc76.udyi Mh satmdis[J].Clherin eveypoGJ.EndVenocrss elsino01,l,2M,etal005,63the675(6)1]Tt o:67 G .[1blom l0 -675526de 455.[7]Iqn Sne nd is 200iakts[balero[9] A,Jorde R,Fts[udeigeweenscpermia.Anstevepweehau Y.sc1 hyJ].y rmisStussoroissuhypJubSer60(Sha]Feum sm[(1)latlipfec, esubineid cialevn catmoidnceelsoneyroh oin in relcho SKpre[13atihombosn tod J].on ineto serum oid6–1):9jecthythyroiroi]wi[12d -he stimulhyl Ilating hormoS,P8]Kne and inthe eft afecweet of t01, coardon[radhyroxine tre sestaves atatmentt a onothl Is[J seS,e04, -rum Thy76.200lipar inoidl):9evels moein subbosis Thyula]wiardjeclhyuncmedts with subclinoidurnicaal icasubl hoT,nceypothy0):latiovroidishe nd Jubm:the ,20et .JCin ,20200oth enTro8,2 inmsois,Study[J]. idypoJ Iicam e rinteaporosrn ionubc70-d,2h o):1n vbosaudlatMed,2006,260Thy(1):53):301. -6[J]1.[8]Kub erudy Ma60(intahaileint):1d,2ly , ear GJ. riudyd p as coesceroCar198dio DS enlat- 2vasculideunc[16200ar 4(4, MnicAn ey fanceand atiatheroge34.ne,olehypetanicresoesvol aspec at]Jal&M]Fets con anary4,8ofssm[m[Jiovubcood inlinhyr SK inica co526sc1l ht a- 5P,enceJ].sub25.ypoHypinorevthyld linroi ald,2moemthdis ut:84y im[J].T1]Thyrvoloid,20ollpal00(10):665-679.[9]Chiero hyche F,,etascJublanulac Catm,Coudemarrt e fM,et aenc,thl.H H ypod ieren tthythyroiI,e6-1aseyordispulciamisntr no:Tht aoidsso]JaciaypoA,H207 hyrostedncebet wingMth anHyp79-incS,Sl hernreasednflm e ca1991):seas iandsm[rotezeidaezeollnnethe01:[10rosvolcleros18-S,eis when cardn Eino201Veniovysteinascrinchiula24.r rsc1 , .Asrad-34ndhiskiallpe factors areacount statued for.C-h o1]T in hyper, elip9,2idee Rpermiac pAn urn omatients[Js i].Atheroscleroslac rois,200artinesur9,203(1):n w26945.- 2tal76.eanJ,Dnd [10]Feld S.Dick9(7ey w o enthyRA. LCAn association ineath].Gt,p , yroe ot ar Syrobetween vab,ne,tioaryardingdegandinioodreess of hypr Tothyroidism and hyl hperrap-cohyrchoienlesterole:Thmia inh i]Lud ihkewomen : tocahe thysk roird n Seru codchinewitoleialntrsterol connection[eattzkJ].HetPrevepventive Cidi200ardionr Sebo as lioodiologyurhldepot, M.l ]Caern,2067-01,4(4):1.l od 79-182ubc.[11]Turhan al.4,8er S,Sezer S,Er61.den G,rompotmthet ioval.Plasma ho]Camoen Iperysteineconceonsre rits[facntrationsthye Rk f and serulhyion12(torurwm lheripid pn b70-9(7palrofile asathn Ice erosc1eron Satitic ripersk stefactors in subcmarlints tr,th199 LCicalhypotothhyroidism[J].Anw ojoryroab,n Saudi Morsed,2008,28(2):96-1ar 01.ntroid[12]Ca]Lunaris GJ [J], Manooidwit:Ril.T stl.Dz N meR , Mayord i G , e M 1-801:rommed6–1on t al.TheCartoloce 455lpeR,WradnfletaimuJ].othIntyroid G ,dis H ].Gbetease prevubcocraleionyroncel&M stlyibetudyre [J]lin.Arlarchivesl I4,8looof internal medicine,200 or0,1Thy60(4):526- 534.[13]with subclinic dsal hypothyroidism[J].ShaseaocaR,Wndo[J]sseesc stngMuyaedical Journrinsseal,2010(24,104,0):icaherocr76–77. dB[14]Jialawitl I su , act isDevd oaraj Sroxe o , entVenugoe fpal SK.C-ismreactiveproteinG ,:84:Risk marker or mediatore H ind,pon atherothrom[J]m ed,pbosnT atmis[tal,thr mJ].Hypertension,2004,44(1):6–11.[tal.L-15]Gumrosienprer aiakeldO,HurwitzS,Perlste[20inTS,etallyi,Avenc.Thyroorslooidfunction aonend -co ut H AE,19]blood prerex9(7thessure home ostasisine uthyreansur faoidu lroxsubdisntrjecAnnts[J].]Lu,etJC linr fEndo-crinn In idisol&MetS t1-8 27ab,,92dep2004,89(7):3jor455-34tal61.[16]Ashyrvolsur dBO,Bjor40)ar oT,Ni lsenT I,etaltt h i.Associatinoionbetorawee idn bloo trd presuyasurean dstzkerumthy roid-stimulat70-ingh or mteroneconncecen tration with ih in theren e fere –a421nceran].Oge:r athytriapopulation do –a–based studylyiartros tr[J].JCatm liubln Er f [Jnd ocrino Inl&Metadisb,2007ini,926,1(5):84nmi1-845.[17]Lubosh itzky R,Aviv d oA,H erer P,eroi hyd,pt a.l Risk factorsfor card iovthe, Gascu lar d isease in w om eduln w ith sub clinicanda l hye-apothyr isV io id ism[J].Thy ro id,20sealyi02,12(5):421- 4ubc25.749ros[18]H ak d,pAE,V isser TcliJ,Drexhage H01:, eA.Sub clin icalhypothyroid d oism is an indep endent risk factor fthycaloratherosclerosis and myocard ial in farction ineld Inerls iern doy w om en:The Rotterdam S tudy[J] an.Ann In ternM ed,2002lyipot,132:270- 278.[19]Cooperand DSes ,Halpern R,Wlyioodter LC,et al.L-thyroxyroinethelinrapy in subclinical hypothyroiiovdism.A double-blind,placebo-co1:7ntrolled triHetal[J].Ann Inter M ed,198heat,p4,101:18-24.[20]Jaeschke R , Guyathytt G , Gerstein H , et al.Doestreatmldeent wiLthth Lthyroicuxine influence health status inmiddle-aged and older adults with subclinicalhypothyroidism [J].G2.ndhen Intern M ed,1996,11:744-749.[21]Molnar I.Cardiovascular consequences of thyroiddiseases,th preir prevalence and treatment,particularlyin cases with subclinical hyper –andhypothyroidism[J].Orv Hetil,2005,146(40):2067-2072.